Zhonghua nei ke za zhi
-
Zhonghua nei ke za zhi · Aug 2013
[The value of changes in end-tidal carbon dioxide pressure induced by passive leg raising test in predicting fluid responsiveness in mechanically ventilated patients with septic shock].
To test whether the changes of partial end-tidal carbon dioxide pressure (PETCO2) during passive leg raising (PLR) predict fluid responsiveness in mechanically ventilated patients with septic shock. ⋯ The change of PETCO2 induced by passive leg raising is a non-invasive and easy way to predict fluid responsiveness in mechanically ventilated patients with septic shock.
-
Zhonghua nei ke za zhi · Aug 2013
Comparative Study[The comparison of different clinical scoring systems for predicting prognosis in acute pancreatitis based on the revised Atlanta classification].
To compare the predictive value of BISAP (bedside index for severity in acute pancreatitis), APACHE II (acute physiology and chronic health evaluation II), and Ranson scoring system in persistent organ failure (POF) and mortality in patients diagnosed as acute pancreatitis (AP) based on the revised Atlanta classification. ⋯ These three clinical scoring systems show modest accuracy for predicting POF or death in AP patients on the early phase based on the revised Atlanta classification. The BISAP scoring system has similar prognostic value to APACHE II and Ranson. However, due to the simplicity and convenience, BISAP scoring system is more popular in clinical practice. Daily scoring on the first 3 days after admission fails to predict the prognosis accurately.
-
Zhonghua nei ke za zhi · Jun 2013
Clinical Trial[The safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis].
To evaluate the safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis (SLED). ⋯ SLED under regional citrate anticoagulation is safe and effective. Citrate achieves satisfying regional anticoagulation effect without interfering systemic clotting function, thus this study provides a new option of SLED anticoagulation for clinicians.
-
Zhonghua nei ke za zhi · Apr 2013
Randomized Controlled Trial Multicenter Study[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
To evaluate the efficacy and safety of human anti-interleukin-6 (IL-6) receptor antibody (tocilizumab) in combination with disease-modifying anti-rheumatoid drugs (DMARDs) for the treatment of rheumatoid arthritis (RA) patients with moderate to severe activity and inadequate response to DMARDs. ⋯ The study showed that tocilizumab combined with DMARDs was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to DMARDs.